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cwant to share some information on the problem of
schemic heart disease in women. Because of a focus on
en, this topic has received inadequate attention, and the
eneral assumption has been that what is true for men is also
rue for women. In this overview, I will try to separate the
acts from the wishful thinking that has evolved on this
opic, largely due to deficiencies in our knowledge base.
ome questions will help to focus this overview. First, how
mportant is ischemic heart disease in women? I will discuss
ome differences observed in clinical outcomes of women
ompared to men and also compared to women without
schemic heart disease. Second, I will deal with some of the
iagnoses and management dilemmas in women with isch-
mic heart disease. Specifically, these include concerns
elated to the meaning of angina, whether women have
ore comorbidities, a different disease, or even gender-
elated bias rather than a different expression of disease. I
ill use two recent projects as sources of new data to
llustrate some important points. Finally, I will suggest what
believe is needed for the future.
ACTS ABOUT THE IMPORTANCE
F ISCHEMIC HEART DISEASE IN WOMEN
ardiovascular disease is the leading cause of death in both
omen and men. Although the number of cardiovascular
eaths has declined in men, it has actually increased in
omen over the past decade. Most of this increase is due to
schemic heart disease and ischemic stroke. And this unfor-
unate trend is primed to continue, because not only is our
opulation aging, but it is being ravaged by the epidemics of
besity, metabolic syndrome, and diabetes—all of which
isproportionately affect women. Considering outpatient
nd inpatient aspects of the problem, annual cost projec-
ions are to be about $400 billion annually. Clearly, this is an
mportant issue.
To get a true picture of the burden of ischemic heart
isease in American women, it seems appropriate to com-
are them with non-American women. Certainly, differ-
From the Division of Cardiovascular Medicine, University of Florida College of
edicine, Gainesville, Florida. Presented at American College of Cardiology Annualrcientific Session 2004, in New Orleans, Louisiana, on March 8, 2004.nces in collection and reporting such data exist among
ountries. However, this cannot fully explain the almost
ve-fold difference in coronary heart disease (CHD) deaths
etween France, Korea, or Japan and the U.S. (1). Even
omen in neighboring countries such as Canada and
exico seem to have fewer CHD deaths than do American
omen. The Eastern European countries and the United
ingdom, have higher death rates than do U.S. women.
Let us move to diagnosis and management. First, some
acts. Previous reports suggest that, compared with men,
linical manifestations of ischemic heart disease in women
ppear approximately 10 or more years later. Women
emonstrate more symptoms and/or noninvasive findings
uggesting ischemic heart disease, yet they have a lower
revalence of luminal obstruction compared to men. Symp-
oms in women, such as chest discomfort and dyspnea, are
ifficult to interpret. Sensitivity and specificity of stress
esting to predict coronary disease are significantly lower in
omen. And women ultimately have poorer outcomes. This
eads to difficulty with clinical decision-making. However,
onsidering some of the biases that have effectively put
omen with ischemic heart disease at a disadvantage to
en, these last two facts should perhaps not be so unex-
ected.
Let us look at some of these biases. For those of us who
ent to medical school or trained from 1969 to the 1980s,
picture from the Netter collection represents what has
een viewed as classical angina pectoris (2). It would be
nusual to visualize a woman carrying a briefcase up steps in
he winter, after eating a meal, clutching her chest, and
omplaining of angina pectoris. This is not the usual
ymptom picture for a woman, but it is easy to see how the
ale bias has been perpetuated. We actually have a very
ncomplete knowledge base on the topic of “female-pattern”
ngina.
Even the more recently developed health outcome tools,
uch as the Seattle Angina Questionnaire, are biased toward
en. Consider that among the almost 5,000 patients with
ngina and coronary disease followed for outcomes in this
roject, only 79 were women (3). Of course, we should not
uestion the conclusion that scores are independently asso-
iated with one-year mortality among outpatients with
oronary disease. Clearly, these scores serve a valuable
isk-stratification role. But how many of you remember the
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Plenary Address May 19, 2004:1727–30rincipal limitation cited by the investigators that the
ndings “. . .need to be confirmed in women”? Considering
hese examples, it is wishful thinking to believe that we have
n understanding of what is “angina” in women and how
uch female-pattern ischemia-related symptoms are linked
o adverse outcomes.
More facts: Compared with men, women have worse
utcomes once they present with obstructive coronary dis-
ase. This clearly is relevant to the need for coronary bypass
urgery where mortality rates in women are approximately
wice that observed in men. For a woman under 65 years of
ge, who has a myocardial infarction (MI), the mortality
ate is approximately twice that for men. Overall, the
ne-year mortality rate for women is about 1.5 times the
ate for men. For heart failure patients of all ages, the annual
ncidence rate for women is about twice that of men. In the
OLVD registry, at one-year follow-up, women had higher
ates of all adverse outcome rates combined compared to
en.
Because time does not permit critical examination of all
hese areas, I will focus on coronary bypass surgery. It is
mportant to know the limitations of the evidence-based
ata that we take for granted when making decisions for
ypass surgery. In all of the seven randomized trials of
oronary artery bypass graft (CABG) surgery versus medical
herapy, which included more than 2,600 stable angina
atients, there were only 85 women (4). The conclusion was
hat the CABG group had a significantly lower mortality at
, 7, and 10 years. But the stated limitations that “the
xclusion of patients 65 years” and “low numbers of
omen” are not generally remembered by physicians. It is
ot surprising, lacking the evidence base to help us make
hoices for women relative to bypass surgery or medical
herapy, that there are low numbers of women relative to
en referred for bypass surgery. Nor should it surprise us
hat women have unusually high adverse outcome rates.
HY THE DIFFERENCE?
here have been suggestions about why women have higher
dverse outcome rates than men. Is it an incomplete
nderstating of the disease? Is it that women have more
omorbidities (e.g., obesity, diabetes, hypertension, in-
reased age), or perhaps is it that ischemic heart disease in
omen is a different disease with a more prominent micro-
ascular component? Or, is it a bias in patient-care patterns?
ll of these as well as other factors have been suggested.
lthough the published literature is extremely limited rel-
tive to women, I believe that data from two recent projects,
NVEST and WISE, offer some important new insights on
hese questions.
The INVEST was an international trial where 22,576
oronary artery disease (CAD) patients were randomized to
wo multi-drug antihypertensive strategies, one anchored by
erapamil, the other by atenolol (5). For the first time in a
andomized CAD trial, 50% of the patients were women. ihe main findings, which I reported at this meeting last
ear in Chicago, showed that blood pressure control overall
as excellent, with more than 70% achieving 140/90 mm
g. Adverse outcomes were equivalent between strategies,
ith fewer cases of new-onset diabetes in the verapamil
trategy.
Not unexpected, women were older than men and 5%
ore were older than 70 years. There were also differences
n ethnicity, with more Hispanic women than Hispanic men
nd fewer Caucasian women than Caucasian men. Women
ad a body mass index higher than men and a lower
revalence of prior MI, which seems consistent with the
igher early MI mortality rates in women. Women had
ore angina, about half of the coronary revascularizations,
ess unstable angina, less smoking, more diabetes, and less
ypercholesterolemia.
Women entered with significantly higher systolic blood
ressure levels than did men, and at any time during
ollow-up they had 2 to 3 mm higher systolic blood pressure
evels than did men. Yet women used more medications and
t the same or higher doses. However, they showed a lower
ercentage of blood pressure control.
Despite higher blood pressure and higher prevalence of
any comorbidities, women had a lower primary outcome
ate—defined as first event among death, MI, or stroke.
his was due to lower rates of death and nonfatal MI, but
ot to stroke compared with men, which was likely related
o their higher blood pressure.
Congestive heart failure, residing in the U.S., prior MI,
nd being female in the U.S. were all significant indepen-
ent predictors of adverse outcomes (death, MI, or stroke).
nterestingly, Hispanic women and multiracial or Asian
omen had lower adverse outcomes, and women in general
ad lower adverse outcomes than did men.
However, when the cohort was restricted to the 10,000
atients with prior MI or coronary revascularization, the
dverse outcome risks were higher among the women. The
ates for death and stroke alone were significantly increased,
ith a trend for nonfatal MI to also be increased in women.
In the cohort restricted to those with prior MI or
evascularization, the multivariate model again identified
eart failure and U.S. residency as associated with increased
isk and also added diabetes, as well as age, renal impair-
ent, smoking, and peripheral vascular disease to the risk
odel. Interestingly, in this restricted cohort adjusted for
hese covariates, the women no longer have a significantly
ower adverse outcome compared with men. These findings
onfirm older and smaller trials relative to more comorbidi-
ies in women. Further, they extend those findings to show
ore difficult-to-control blood pressure and suggest that a
arge component of the gender difference in outcomes is
elated to comorbid conditions that are more frequent in
omen than in men.
I will share with you some new data from the WISE
tudy, a four-center, NHLBI study that evaluated approx-
mately 1,000 women with suspected ischemia referred for
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May 19, 2004:1727–30 Plenary Addresslective diagnostic coronary angiography. Almost all of
hese women had chest discomfort, and the objectives were
o investigate new and diagnostic pathophysiologic mecha-
isms and to better characterize outcomes in the absence of
ow-limiting stenoses by angiography.
Angiographic findings of this cohort of women showed
hat only 38% of the women had 50% or greater stenosis.
hese were evenly divided, with 19% having one-vessel
bstruction and 19% with two- and three-vessel obstruc-
ion. This confirms several prior studies that found the
ajority of women presenting with symptoms and/or signs
uggesting ischemic heart disease have no stenosis or 50%
tenosis. It is this subgroup that is of particular interest.
A presentation later this week will summarize four-year,
isk-adjusted outcomes by extent of coronary disease (6).
here was a 9.4% death or MI rate (or about 2.7% annually)
n the subgroup with no or minimal disease by angiography.
his is an unacceptable event rate.
Another presentation will summarize the estimated life-
ime cost of care for cardiovascular disease by the angio-
raphic extent of disease (7). Even women with no disease
y angiography have in excess of $750,000 for lifetime costs
or care. In an era of shrinking health care resources, such a
nding also is unacceptable.
We have been particularly interested in the subgroup of
omen without apparent angiographic obstruction. In a
ISE substudy, the arteries of these women were examined
sing intravascular ultrasound (IVUS). Our findings indi-
ate that 80% of women with so-called “normal angio-
rams” have plaque lesions by IVUS and the vast majority
ave multiple lesions.
In a recent report from our institution, a cohort of 163 of
hese women underwent coronary artery reactivity testing
sing acetylcholine (8). Women who failed to dilate had
ore cardiac events over follow-up than did the women
ho dilated. This persisted in a multivariate model where
ross-sectional area response to acetylcholine was an inde-
endent predictor of four-year outcome.
These findings illustrate a pervasive myth that I have
iven the less than eloquent name of “myth of angina with
ormal coronary arteries in women as a benign syndrome.”
his myth has contributed to some of the bias related to the
anagement of women with so-called normal coronary
rteries and is based upon 3,000 cases in the literature.
ith few exceptions, long-term follow-up in these studies
s too brief to account for the delay in presentation of
omen compared to men. All of these studies were retro-
pective, and none used core laboratory angiographic find-
ngs. Translated into practice, these studies led to the
ismissal of subspecialty care for an important subgroup of
omen—who were consequently disregarded by primary
aregivers as having benign symptoms. The end result was
n extremely important missed opportunity for cardiovas-
ular prevention in far too many women. pECAPITULATION
rom the foregoing it is apparent that much of our thinking
elative to ischemic heart disease in women was wishful
hinking. This thinking, as summarized by the examples in
able 1, has contributed to our lack of understanding of this
roblem. Perhaps now that we recognize these limitations
e can move forward. Some of the exciting new work relates
o diagnostic evaluations in women.
Relative to newer diagnostic techniques, later this week
ew and innovative data will be presented among WISE
omen comparing single-photon emission computed to-
ography (SPECT) and magnetic resonance imaging
MRI) global and regional myocardial perfusion status.
indings in 133 women undergoing evaluation for chest
ain as part of the WISE project show a global myocardial
erfusion derived from MRI is superior for identifying
omen at high risk for adverse outcomes compared with
PECT and MRI regional ischemia scar analyses (9).
onsiderable data link the microvasculature to ischemia
mong these women without severe obstructive lesions.
New data will be presented on hemoglobin (Hgb) alone
nd Hgb combined with inflammatory markers, suggesting
hat a multimarker panel may be useful to identify women at
igh risk for adverse events (10).
HERE DO WE GO FROM HERE?
here are a number of important steps that we all must take
o bring this situation under control and ensure that we are
iving female patients the highest quality care possible.
irst, we must increase awareness among women about their
isk of heart disease. Second, we must teach—or re-teach—
hysicians to pay more attention to symptoms and test
ndings. We must also begin to better understand that there
s a “female pattern” of ischemia-related symptoms distinct
rom that seen in men. We must come to grips with the fact
hat a “clean” angiogram in a symptomatic woman does not
ean her long-term outcome is benign. And more research
eeds to be done looking at issues like concealed plaque
e.g., remodeling) and inflammation in the vessel wall, the
rognostic utility of blood markers, and the role of the
icrovasculature. Finally, and this is true for all of our
able 1. Ischemic Heart Disease in Women: Diagnosis and
anagement
ome Examples of Wishful Thinking Over the Years:
What is true for men is also true for women.
Hormone replacement therapy prevents cardiovascular disease.
Seattle Angina Questionnaire scores independently predict morbidity
and mortality among women with coronary artery disease.
Women undergoing coronary artery bypass graft surgery have lower
mortality than those treated medically.
Women with angina and “normal coronary angiograms” have a benign
long-term outcome.atients, it is absolutely imperative that we all apply
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ypertension, obesity, and diabetes.
The first action step I mentioned was the need to raise
omen’s awareness of their risk of heart disease. The ACC
ntends to play an important role in this effort. Last month
was a guest at the White House when President and Mrs.
ush kicked off American Heart Month. After this session,
will recognize Mrs. Bush’s strong support for the aware-
ess campaigns with an honorary fellowship in the ACC
Fig. 1). Just this past week, we held our first community
vent, the primary aim of which was to bring attention to
his very issue. The event was conducted in collaboration
ith the NHLBI and AHA and their respective women’s
wareness campaigns, both of which the ACC supports.
he event, hosted by our Louisiana ACC Chapter, was an
stounding success, attracting hundreds of visitors and
enerating media coverage to ensure that the message is
pread far and wide.
These awareness campaigns could not come at a more
mportant time. Surveys have shown that women do not
elieve heart disease is something they need to worry about. In
ne survey, 87% of women cited cancer as their greatest
oncern, even though cardiovascular disease kills nearly twice as
any women each year as do all forms of cancer combined.
The ACC will continue to support these campaigns and
nsure that the Red Dress, the common symbol of these
igure 1. Laura Bush accepts an honorary fellowship from Dr. Pepine.ampaigns, becomes as ubiquitous as the pink ribbon of breastancer awareness. Women must receive the message loud and
lear: Heart disease is not relegated to men. You, too, are at risk.
end correspondence to: Carl J. Pepine, MD, MACC, Professor
nd Chief, Division of Cardiovascular Medicine, University of Florida
ollege of Medicine, Box 100277, 1600 Archer Road, Gainesville,
lorida 32610-0277. E-mail: pepincj@medicine.ufl.edu.
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